Zevra Therapeutics, Inc. Treasury Stock, Value, Acquired, Cost Method
Shares the company repurchased and the cash it paid, as filed in its 10-Q and 10-K XBRL (statement of shareholders' equity and cash flow statement).
- Zevra Therapeutics, Inc. treasury stock, value, acquired, cost method for the quarter ending 2023-03-31 was $3.45M, a 27.02% decline year-over-year.
- Zevra Therapeutics, Inc. treasury stock, value, acquired, cost method for the quarter ending 2022-03-31 was $4.72M.
- Zevra Therapeutics, Inc. treasury stock, value, acquired, cost method for fiscal 2023 was $3.45M, a 27.02% decline from fiscal 2022.
- Zevra Therapeutics, Inc. treasury stock, value, acquired, cost method for fiscal 2022 was $4.72M, a 67.84% increase from fiscal 2021.
- Zevra Therapeutics, Inc. treasury stock, value, acquired, cost method for fiscal 2021 was $2.81M.
| Period end | Treasury Stock, Value, Acquired, Cost Method 3 month | Treasury Stock, Value, Acquired, Cost Method 12 month |
|---|---|---|
| 2023-12-31 | $3.45M 10-K · filed 2025-03-12 | |
| 2023-03-31 | $3.45M 10-Q · filed 2024-11-13 | |
| 2022-12-31 | $4.72M 10-K · filed 2024-04-01 | |
| 2022-03-31 | $4.72M 10-K · filed 2024-04-01 | |
| 2021-12-31 | $2.81M 10-K · filed 2023-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |